OBJECTIVES: The aim of this research is to investigate whether HA filler influences the initiation of an autoimmune reaction in healthy women who had received HA filler by screening for autoantibodies in the blood. Results will be compared with agematched apparently healthy control women who did not receive the filler.
METHODS: Serum samples were obtained from 44 females who had received HA filler and 44 females who had not as a control group. The enzyme-linked immunosorbent assay (ELISA) technique was utilised to measure serum concentrations of anti- Thyroglobulin (Tg), anti -thyroid peroxidase (TPO), rheumatoid factor (RF), anti-nuclear antibody (ANA) and anticentromeres.
RESULTS: The number of women who tested positive for the measured autoantibodies was not statistically significant (p=0.803) between those who had received HA filler (n=10/44, 25%) and the control group (n=11/44, 22.7%).
CONCLUSION: Based on our result HA filler procedures do not induce an autoimmune reaction in women who received HA filler compared to controls. And consequently, HA filler procedures are relatively safe, and these results contradict the findings of other non-controlled works.
MATERIALS AND METHODS: The study included 99 patients with SLE who attended the Rheumatology Unit at Baghdad Teaching Hospital. These subjects were divided into three subgroups according to disease status: inactive, n = 33; active moderate, n = 33; and active severe, n = 33. Additionally, 33 matched controls were studied. Full medical histories, body mass index, gender and clinical disease activity, the latter evaluated with the SLE disease activity index, were collected. Laboratory parameters measured included anti-dsDNA antibodies, C3 and C4 levels, erythrocyte sedimentation rate and C-reactive protein titres. Serum IL-40 levels were quantified using an enzyme-linked immunosorbent assay.
RESULTS: IL-40 levels were significantly higher in patients (12.5420 ± 3.00575 ng/L) than in controls (6.1138 ± 0.59452 ng/L; p < 0.01). Mean serum IL-40 concentration was highest in the active severe group (15.2291 ± 2.26540 ng/L) and decreased, in order of disease severity, in the remaining cohorts: active moderate, 13.0643 ± 1.23927 ng/L; inactive, 9.3325 ± 1.62807 ng/L (P < 0.01); controls, 6.1138 ± 0.59452 ng/L. Serum IL-40 levels showed excellent validity for the diagnosis of SLE with a cut-off value of ≥ 9.3 ng/ml and area under the curve of 0.987. Sensitivity, specificity and accuracy were 99%, 90.9% and 96.97%, respectively (P < 0.001).
CONCLUSIONS: Serum IL-40 levels were elevated in SLE patients. It is therefore proposed that IL-40 is a novel cytokine which is associated with SLE and positively linked with disease severity.